$160 Million is the total value of Opaleye Management Inc.'s 52 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGMO | Exit | SANGAMO BIOSCIENCES INC | $0 | – | -60,000 | -100.0% | -0.23% | – |
| Exit | ACHAOGEN INC | $0 | – | -125,000 | -100.0% | -0.30% | – | |
| VTAE | Exit | VITAE PHARMACEUTICALS INC | $0 | – | -58,500 | -100.0% | -0.44% | – |
| MGNX | Exit | MACROGENICS INC | $0 | – | -35,000 | -100.0% | -0.45% | – |
| CLLS | Exit | CELLECTIS S Asponsored ads | $0 | – | -50,000 | -100.0% | -0.65% | – |
| AXDX | Exit | ACCELERATED DIAGNOSTICS INC | $0 | – | -75,000 | -100.0% | -0.67% | – |
| ALDR | Exit | ALDER BIOPHARMACEUTICALS INC | $0 | – | -65,000 | -100.0% | -0.90% | – |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -150,000 | -100.0% | -0.92% | – |
| AGRX | Exit | AGILE THERAPEUTICS INC | $0 | – | -300,000 | -100.0% | -1.22% | – |
| FLML | Exit | FLAMEL TECHNOLOGIES SAsponsored adr | $0 | – | -250,000 | -100.0% | -1.28% | – |
| NBIX | Exit | NEUROCRINE BIOSCIENCES INC | $0 | – | -55,000 | -100.0% | -1.30% | – |
| Exit | LA JOLLA PHARMACEUTICAL CO | $0 | – | -140,000 | -100.0% | -1.58% | – | |
| AVGR | Exit | AVINGER INC | $0 | – | -190,000 | -100.0% | -1.80% | – |
| TNXP | Exit | TONIX PHARMACEUTICALS HLDG C | $0 | – | -565,000 | -100.0% | -1.81% | – |
| CEMP | Exit | CEMPRA INC | $0 | – | -200,000 | -100.0% | -2.60% | – |
| RLYP | Exit | RELYPSA INC | $0 | – | -220,000 | -100.0% | -2.61% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2016-05-27
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-31 |
| 13F-HR/A | 2024-05-29 |
| 4 | 2024-05-23 |
| 4 | 2024-05-17 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-10 |
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.